Jean-Michel Henlin

USPTO Granted Patents = 17 (Patent Applications = 7)

CIPO Patents = 6 (Patent Applications = 2)

EPO Patents = 6 (Patent Applications = 10)

Average Co-Inventor Count = 13.2

ph-index = 3

Forward Citations = 30(Granted Patents)

Company Filing History:

Les Laboratoires Servier

patents

2 out of 53

Les Laboratories Servier

where one patent can have more than one assignee

Years Active: 2015-2021

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11058689 - Pyrrole compounds, a process for their preparation and pharmaceutical (2021-07-13),

2. 11028070 - Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them (2021-06-08),

3. 10689364 - Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them (2020-06-23),

4. 10688101 - Pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them (2020-06-23),

5. 10662173 - Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them (2020-05-26),

6. 10414754 - Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them (2019-09-17),

7. 10265323 - Pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them (2019-04-23),

8. 10258626 - Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them (2019-04-16),

9. 9944620 - Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them (2018-04-17),

10. 9809574 - Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them (2017-11-07),

11. 9765056 - Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them (2017-09-19),

12. 9603854 - Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them (2017-03-28),

13. 9598427 - Pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them (2017-03-21),

14. 9597341 - Phosphate compounds, a process for their preparation and pharmaceutical compositions containing them (2017-03-21),

15. 9120791 - Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them (2015-09-01),

Title: The Innovative Contributions of Jean-Michel Henlin

Introduction

Jean-Michel Henlin is a prominent inventor based in Suresnes, France. He has made significant contributions to the field of medicinal chemistry, holding a total of 17 patents. His work focuses on developing compounds that have therapeutic applications, particularly in treating serious health conditions.

Latest Patents

Among his latest patents are innovative pyrrole compounds and isoindoline or isoquinoline compounds. The pyrrole compounds are designed for pharmaceutical applications, particularly in treating pathologies involving a deficit in apoptosis, such as cancer and autoimmune diseases. The isoindoline or isoquinoline compounds also serve as medicinal products that act as pro-apoptotic agents, providing potential treatments for various health conditions.

Career Highlights

Jean-Michel Henlin has worked with notable companies in the pharmaceutical industry, including Vernalis Limited and Les Laboratoires Servier. His experience in research and development has allowed him to contribute to the advancement of medicinal products that address critical health issues.

Collaborations

Throughout his career, Henlin has collaborated with esteemed colleagues, including Thierry Le Diguarher and James Edward Paul Davidson. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his work.

Conclusion

Jean-Michel Henlin's innovative contributions to medicinal chemistry and his extensive patent portfolio underscore his importance in the field. His work continues to pave the way for new therapeutic solutions that can improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.